Cargando…
Multi-omics analysis uncovers tumor ecosystem dynamics during neoadjuvant toripalimab plus nab-paclitaxel and S-1 for esophageal squamous cell carcinoma: a single-center, open-label, single-arm phase 2 trial
BACKGROUND: Immune checkpoint inhibitors combined with chemotherapy as a neoadjuvant therapy have been applied to the treatment of esophageal squamous cell carcinoma (ESCC). However, the optimal regimen needs to be further explored, particularly for older patients, and the mechanisms by which the im...
Autores principales: | Zhang, Guoqing, Yuan, Jing, Pan, Chaohu, Xu, Qing, Cui, Xiaoli, Zhang, Jing, Liu, Minglu, Song, Zhigang, Wu, Liangliang, Wu, Dongfang, Luo, Haitao, Hu, Yi, Jiao, Shunchang, Yang, Bo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10024111/ https://www.ncbi.nlm.nih.gov/pubmed/36921563 http://dx.doi.org/10.1016/j.ebiom.2023.104515 |
Ejemplares similares
-
Durable Response and Good Tolerance to the Triple Combination of Toripalimab, Gemcitabine, and Nab-Paclitaxel in a Patient With Metastatic Pancreatic Ductal Adenocarcinoma
por: Shui, Lin, et al.
Publicado: (2020) -
Study protocol for an open-label, single-arm, phase Ib/II study of combination of toripalimab, nab-paclitaxel, and gemcitabine as the first-line treatment for patients with unresectable pancreatic ductal adenocarcinoma
por: Shui, Lin, et al.
Publicado: (2020) -
Paclitaxel/toripalimab: Leucopenia and gastrointestinal reaction: case report
Publicado: (2021) -
Neoadjuvant nab-paclitaxel in the treatment of breast cancer
por: Ueno, Naoto T., et al.
Publicado: (2016) -
Nab-Paclitaxel in combination with Cisplatin Versus Docetaxel Plus Cisplatin as First-Line Therapy in Non-small Cell Lung Cancer
por: Chen, Yi, et al.
Publicado: (2017)